Home › Neoplasms by Histologic Type › Massachusetts › Boston
Neoplasms by Histologic Type clinical trials in Boston, MA
5 studies for Neoplasms by Histologic Type are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RecruitingObservational study
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
RecruitingPhase 1
- Massachusetts General Hospital, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- Beth Israel Deaconess Medical Center, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
- Massachusetts General Hospital,, Boston
Neoplasms by Histologic Type trials in other cities
- Atlanta, GA5 studies
- Houston, TX4 studies
- Los Angeles, CA4 studies
- Chicago, IL4 studies
- St. Louis, MO3 studies
- San Francisco, CA3 studies
- Baldwin Park, CA3 studies
- New York City, NY3 studies
- Nashville, TN3 studies
- Tampa, FL3 studies
- Dallas, TX3 studies
- Clifton, NJ3 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.